Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019 December 3, 2019
Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis December 2, 2019
Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science Demonstrating First Complete Chemical Synthesis of Bicyclic Ring of a Mutacin 1140 Analog November 15, 2019
Oragenics, Inc. SVP of Discovery Research, Martin Handfield, Ph.D. to Be Featured Speaker at the International Conference on Microbial Research and Applications November 11, 2019
Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019 September 30, 2019
Oragenics, Inc. Announces Phase 2 Clinical Trial of AG013 Reaches Enrollment of 158 Patients September 25, 2019
Oragenics, Inc. to Present Interim Data on AG013 at the European Society of Medical Oncology Congress September 23, 2019
Oragenics Inc. to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference September 6, 2019
Oragenics, Inc. to Present Overview of Lantibiotics Pipeline at the Annual Military Health System Research Symposium August 20, 2019
